Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 3/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712851 | 0.83 | IDO1 (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL157921 | 0.83 | IDO1 (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5000353 | 0.83 | IDO1 (0.51) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27516403 | 0.83 | IDO1 (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11502956 | 0.83 | IDO1 (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11502955 | 0.83 | IDO1 (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2366457 | 0.80 | MEN1 (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9729607 | 0.80 | HTT (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2366462 | 0.80 | MEN1 (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12082173 | 0.80 | MEN1 (0.50) | IDO1MAPK1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102272107-B | Pyrimidine derivatives and their use for combating undesired vegetation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-14 | — | — | CN | disclosed |
| CN-104203925-A | 5-aminopyrimidine derivatives and use thereof for combating undesired plant growth | BAYER IP GMBH | 2014-12-10 | — | — | CN | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-2595985-A1 | ISOXAZOLE, ISOTHIAZOLE, FURANE AND THIOPHENE COMPOUNDS AS MICROBICIDES | Syngenta Participations AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2595984-A1 | MICROBICIDES | Syngenta Participations AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-12-20 | — | — | US | disclosed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8263599-B2 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| WO-2012010568-A1 | MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010567-A1 | ISOXAZOLE, ISOTHIAZOLE, FURANE AND THIOPHENE COMPOUNDS AS MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-5466821-A | Triazole ring containing fungicides, intermediates | ZENECA LIMITED (GB) | 1995-11-14 | — | — | US | disclosed |
| US-5194441-A | Fungicides | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-16 | — | — | US | disclosed |
| US-5171354-A | Herbicides | CIBA-GEIGY CORPORATION (US) | 1992-12-15 | — | — | US | disclosed |
| US-4501746-A | HERBICIDES; PLANT GROWTH REGULATORS | ELI LILLY AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | IDO1 20/4885MAPK1 3473/4885CYP1A2 104/4885 |
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | IDO1 247/4885MAPK1 1289/4885CYP1A2 79/4885 |
| US-20120322807-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | IDO1 1514/4885MAPK1 136/4885CYP1A2 3133/4885 |
| US-20100210661-A1 | STAT3/5 ACTIVATION INHIBITOR | STAT3, JAK2, STAT1 | IDO1 974/4885MAPK1 135/4885CYP1A2 2665/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | IDO1 495/4885MAPK1 219/4885CYP1A2 979/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | IDO1 279/4885MAPK1 2765/4885CYP1A2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.